- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Acquisitions boost Alliance growth
Alliance Imaging CEO Richard Zehner is looking for acquisitionsto buttress the Orange, CA, company's claim that it is the nation'slargest mobile MRI and CT fleet. Alliance announced record third-quarter earnings and strong revenueresults on Oct. 17,
Alliance Imaging CEO Richard Zehner is looking for acquisitionsto buttress the Orange, CA, company's claim that it is the nation'slargest mobile MRI and CT fleet.
Alliance announced record third-quarter earnings and strong revenueresults on Oct. 17, five days after revealing that it had takendelivery of a GE 1-tesla Signa MRI to be deployed on a new routein Missouri.
For the third quarter (end-September), Alliance reported netincome of $1.4 million on revenues of $15.1 million. For the firstnine months of 1995, Alliance earned $3.6 million on revenuesof $44.3 million.
In the third quarter of last year, the company had a net lossof $1.4 million on revenues of $14.2 million. For the first ninemonths of 1994, it posted a net loss of $3.5 million on revenuesof $42.9 million.
Alliance also ended the period with a cash balance of over $10million, which in part is earmarked to buy competing mobile companies,according to Zehner.
"We're actively seeking and evaluating corporate acquisitionsto generate higher profitability and revenues from greater marketshare," he said.
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.
